Literature DB >> 12351419

Human leukocyte antigens class II and tumor necrosis factor genetic polymorphisms are independent predictors of non-Hodgkin lymphoma outcome.

Przemyslaw Juszczynski1, Ewa Kalinka, Jacques Bienvenu, Grzegorz Woszczek, Maciej Borowiec, Tadeusz Robak, Marek Kowalski, Ewa Lech-Maranda, Lucile Baseggio, Bertrand Coiffier, Gilles Salles, Krzysztof Warzocha.   

Abstract

Tumor necrosis factor (TNF) production and non-Hodgkin lymphoma (NHL) outcome was found to be related to the TNF(-308) polymorphism. To explore whether this could be linked to neighboring polymorphisms, we genotyped the TNF(-376,-308,-238,-163), lymphotoxin alpha (LTalpha)(+252), and HLA DRB1 alleles in 204 patients with NHL and 120 controls. TNF(-308A) was the only allele associated with higher TNF and its p55 and p75 receptors' levels (P =.009, P =.03, and P =.007) and lower complete remission rates (P =.006). Freedom from progression (FFP) and overall survival (OS) were shorter in patients with TNF(-308A) (P =.009 and P =.02), null HLA DRB1*02 allele (P =.007 and P =.14), or both genetic markers (P =.004 and P =.005). Multivariate analysis incorporating International Prognostic Index (IPI) identified TNF(-308A) (P <.0001, relative risk [RR] = 1.63; P <.0001, RR = 1.51) and null HLA DRB1*02 alleles (P =.015, RR = 1.18; P <.0001, RR = 1.25) as independent factors for FFP and OS. These results indicate the existence of at least 2 inherited factors involved in NHL outcome.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12351419     DOI: 10.1182/blood-2002-02-0654

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  29 in total

1.  Prognostic significance of host immune gene polymorphisms in follicular lymphoma survival.

Authors:  James R Cerhan; Sophia Wang; Matthew J Maurer; Stephen M Ansell; Susan M Geyer; Wendy Cozen; Lindsay M Morton; Scott Davis; Richard K Severson; Nathaniel Rothman; Charles F Lynch; Sholom Wacholder; Stephen J Chanock; Thomas M Habermann; Patricia Hartge
Journal:  Blood       Date:  2007-02-27       Impact factor: 22.113

2.  Genetic variation in 1253 immune and inflammation genes and risk of non-Hodgkin lymphoma.

Authors:  James R Cerhan; Stephen M Ansell; Zachary S Fredericksen; Neil E Kay; Mark Liebow; Timothy G Call; Ahmet Dogan; Julie M Cunningham; Alice H Wang; Wen Liu-Mares; William R Macon; Diane Jelinek; Thomas E Witzig; Thomas M Habermann; Susan L Slager
Journal:  Blood       Date:  2007-09-07       Impact factor: 22.113

3.  Host immune gene polymorphisms in combination with clinical and demographic factors predict late survival in diffuse large B-cell lymphoma patients in the pre-rituximab era.

Authors:  Thomas M Habermann; Sophia S Wang; Matthew J Maurer; Lindsay M Morton; Charles F Lynch; Stephen M Ansell; Patricia Hartge; Richard K Severson; Nathaniel Rothman; Scott Davis; Susan M Geyer; Wendy Cozen; Stephen J Chanock; James R Cerhan
Journal:  Blood       Date:  2008-07-16       Impact factor: 22.113

4.  Cytokine gene polymorphisms and progression-free survival in classical Hodgkin lymphoma by EBV status: results from two independent cohorts.

Authors:  Hervé Ghesquières; Matthew J Maurer; Olivier Casasnovas; Stephen M Ansell; Beth R Larrabee; Eva Lech-Maranda; Anne J Novak; Anne-Laure Borrel; Susan L Slager; Pauline Brice; Cristine Allmer; Annie Brion; Steven C Ziesmer; Franck Morschhauser; Thomas M Habermann; Isabelle Gaillard; Brian K Link; Aspasia Stamatoullas; Christophe Fermé; Ahmet Dogan; William R Macon; Josée Audouin; James R Cerhan; Gilles Salles
Journal:  Cytokine       Date:  2013-09-03       Impact factor: 3.861

5.  Genetic variation in tumor necrosis factor and lymphotoxin-alpha (TNF-LTA) and breast cancer risk.

Authors:  Mia M Gaudet; Kathleen M Egan; Jolanta Lissowska; Polly A Newcomb; Louise A Brinton; Linda Titus-Ernstoff; Meredith Yeager; Stephen Chanock; Robert Welch; Beata Peplonska; Amy Trentham-Dietz; Montserrat Garcia-Closas
Journal:  Hum Genet       Date:  2007-01-11       Impact factor: 4.132

6.  Risk Factors of Non-Hodgkin Lymphoma.

Authors:  Yawei Zhang; Ying Dai; Tongzhang Zheng; Shuangge Ma
Journal:  Expert Opin Med Diagn       Date:  2011-11-01

Review 7.  Tumor necrosis factor and cancer, buddies or foes?

Authors:  Xia Wang; Yong Lin
Journal:  Acta Pharmacol Sin       Date:  2008-11       Impact factor: 6.150

8.  Association of tumor necrosis factor genetic polymorphism with chronic atrophic gastritis and gastric adenocarcinoma in Chinese Han population.

Authors:  Bao-Ying Fei; Bing Xia; Chang-Sheng Deng; Xiao-Qing Xia; Min Xie; J Bart A Crusius; A Salvador Pena
Journal:  World J Gastroenterol       Date:  2004-05-01       Impact factor: 5.742

9.  Genetic variation in B-cell-activating factor is associated with an increased risk of developing B-cell non-Hodgkin lymphoma.

Authors:  Anne J Novak; Susan L Slager; Zachary S Fredericksen; Alice H Wang; Michelle M Manske; Steven Ziesmer; Mark Liebow; William R Macon; Stacey R Dillon; Thomas E Witzig; James R Cerhan; Stephen M Ansell
Journal:  Cancer Res       Date:  2009-04-21       Impact factor: 12.701

10.  TNF-β +252 A>G polymorphism and susceptibility to cancer.

Authors:  Lin Yang; Rennan Feng; Guiyou Liu; Mingzhi Liao; Liangcai Zhang; Wenbo Wang
Journal:  J Cancer Res Clin Oncol       Date:  2013-02-03       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.